PACMAN-AMI事后分析:急性心梗患者强化降脂的病灶水平效应
该研究为PACMAN-AMI随机临床试验的事后病灶水平分析,纳入245例急性心梗患者共591个非罪犯病灶(斑块负荷≥40%)。
要点
- 阿利西尤单抗联合高强度他汀在病灶水平显著促进PAV消退。
- 阿利西尤单抗组MLA增大,而安慰剂组MLA减小。
- 阿利西尤单抗促进脂质丰富斑块向非脂质丰富表型转变。
核心结论
- 在病灶水平,强化降脂治疗诱导的PAV消退程度大于既往血管水平分析所描述的程度。
- 与单用他汀相比,阿利西尤单抗治疗与病灶MLA更大程度增大及高危斑块表型更频繁向稳定表型转变相关。
研究设计与样本
- PACMAN-AMI随机临床试验的事后病灶水平分析(入组2017年5月至2020年10月,末次随访2021年10月)。
- 急性心梗患者随机接受阿利西尤单抗或安慰剂联合高强度他汀治疗。
- 非罪犯病灶定义为IVUS斑块负荷≥40%的节段,共纳入245例患者591个病灶(阿利西尤单抗组287个病灶/118例,安慰剂组304个病灶/127例)。
- 基线和52周随访的IVUS、近红外光谱和OCT图像由对治疗分配设盲的读者手动匹配。
临床怎么用
- 对急性心梗后高危斑块患者,可考虑在强化他汀基础上加用阿利西尤单抗以促进斑块稳定。
- 病灶水平影像学评估有助于更精细评价降脂治疗的斑块修饰效应。
局限性
- 本研究为事后病灶水平分析,结果需谨慎解读。
- 仅纳入非罪犯病灶且要求斑块负荷≥40%,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous studies investigated atherosclerotic changes induced by lipid-lowering therapy in extensive coronary segments irrespective of baseline disease burden (a vessel-level approach). OBJECTIVE: To investigate the effects of lipid-lowering therapy on coronary lesions with advanced atherosclerotic plaque features and presumably higher risk for future events. DESIGN, SETTING, AND PARTICIPANTS: The PACMAN-AMI randomized clinical trial (enrollment: May 2017 to October 2020; final follow-up: October 2021) randomized patients with acute myocardial infarction to receive alirocumab or placebo in addition to high-intensity statin therapy. In this post hoc lesion-level analysis, nonculprit lesions were identified as segments with plaque burden 40% or greater defined by intravascular ultrasound (IVUS). IVUS, near-infrared spectroscopy, and optical coherence tomography images at baseline and the 52-week follow-up were manually matched by readers blinded to treatment allocation. Data for this study were analyzed from October 2022 to November 2023. INTERVENTIONS: Alirocumab or placebo in addition to high-intensity statin therapy. MAIN OUTCOMES AND MEASURES: Lesion-level imaging outcome measures, including high-risk plaque characteristics and phenotypes. RESULTS: Of the 245 patients in whom lesions were found, 118 were in the alirocumab group (mean [SD] age, 58.2 [10.0] years; 101 [85.6%] male and 17 [14.4%] female) and 127 in the placebo group (mean [SD] age, 57.7 [8.8] years; 104 [81.9%] male and 23 [18.1%] female). Overall, 591 lesions were included: 287 lesions (118 patients, 214 vessels) in the alirocumab group and 304 lesions (127 patients, 239 vessels) in the placebo group. Lesion-level mean change in percent atheroma volume (PAV) was -4.86% with alirocumab vs -2.78% with placebo (difference, -2.02; 95% CI, -3.00 to -1.05; P < .001). At the minimum lumen area (MLA) site, mean change in PAV was -10.14% with alirocumab vs -6.70% with placebo (difference, -3.36; 95% CI, -4.98 to -1.75; P < .001). MLA increased by 0.15 mm2 with alirocumab and decreased by 0.07 mm2 with placebo (difference, 0.21; 95% CI, 0.01 to 0.41; P = .04). Among 122 lipid-rich lesions, 34 of 55 (61.8%) in the alirocumab arm and 27 of 67 (41.8%) in the placebo arm showed a less lipid-rich plaque phenotype at follow-up (P = .03). Among 63 lesions with thin-cap fibroatheroma at baseline, 8 of 26 (30.8%) in the alirocumab arm and 3 of 37 (8.1%) in the placebo arm showed a fibrous/fibrocalcific plaque phenotype at follow-up (P = .02). CONCLUSIONS AND RELEVANCE: At the lesion level, very intensive lipid-lowering therapy induced substantially greater PAV regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion MLA and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03067844.
引用
- Biccirè, Kakizaki, Koskinas, et al. Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the PACMAN-AMI Trial. JAMA Cardiol. 2024. PMID: 39221516. doi:10.1001/jamacardio.2024.3200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。